Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: A phase iii clinical trial

Journal of Sexual Medicine

Volumn 7, Issue 5, 2010, Pages 1928-1936

  Glina, Sidney ^a   Fonseca, Gilvan N ^b   Bertero, Eduardo B ^c   Damião, Ronaldo ^d   Rocha, Luíz C A ^e   Jardim, Carlos R F ^f   Cairoli, Carlos E ^g   Teloken, Cláudio ^h   Torres, Luiz O ⁱ   Faria, Geraldo E ^j   da Silva, Marcelo B ^k   Pagani, Eduardo ^l  

^a HOSPITAL IPIRANGA   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c Clínica de Urologia Bertero   (Brazil)

^d HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^f HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^g PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^h UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

ⁱ Clinica de Urologia e Andrologia   (Brazil)

^j Instituto de Urologia e Nefrologia de Rio Claro   (Brazil)

^k Hospital Santo Amaro   (Brazil)

^l Cristalia Produtos Químicos Farmacêuticos LTDA ^*  (Brazil)

more..

Author keywords

Erectile Dysfunction; Lodenafil Carbonate; Phosphodiesterase 5 (PDE5)

Indexed keywords

LODENAFIL CARBONATE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; CARBONIC ACID DERIVATIVE; LODENAFIL; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BRAZIL; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; DYSPNEA; EPIPHORA; ERECTILE DYSFUNCTION; EYE PAIN; FATIGUE; FLUSHING; HEADACHE; HUMAN; INFLUENZA; INTERNATIONAL INDEX OF ERECTILE FUNCTION; LABYRINTHITIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NAUSEA; ORGASM; PENIS ERECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SIDE EFFECT; THORAX PAIN; VISUAL DISORDER; XEROSTOMIA; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PATIENT SATISFACTION; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; CARBONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 77953566605     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01711.x     Document Type: Article

References (37)

1. Chew KK, Bremner A, Jamrozik K, Earle C, Stuckey B. Male erectile dysfunction and cardiovascular disease: Is there an intimate nexus? J Sex Med 2008, 5:928-34.
2. Teles AG, Carreira M, Alarcão V, Sociol D, Aragüés JM, Lopes L, Mascarenhas M, Costa JG. Prevalence, severity, and risk factors for erectile dysfunction in a representative sample of 3,548 Portuguese men aged 40-69 years attending primary healthcare centers: Results of the Portuguese erectile dysfunction study. J Sex Med 2008, 5:1317-24.
3. Walz J, Perrotte P, Suardi N, Hutterer G, Jeldres C, Bénard F, Valiquette L, Graefen M, Montorsi F, Karakiewicz PI. Baseline prevalence of erectile dysfunction in a prostate cancer screening population. J Sex Med 2008, 5:428-35.
4. Chew KK, Stuckey B, Bremner A, Earle C, Jamrozik K. Male erectile dysfunction: Its prevalence in Western Australia and associated sociodemographic factors. J Sex Med 2008, 5:60-9.
5. Moreira ED, Bestane WJ, Bartolo EB, Fittipaldi JA. Prevalence and determinants of erectile dysfunction in Santos, Southeastern Brazil. Sao Paulo Med J 2002, 120:49-54.
6. Abdo CH, Oliveira WM, Scanavino MT, Martins FG. Erectile dysfunction: Results of the Brazilian Sexual Life Study. Rev Assoc Med Bras 2006, 52:424-9.
7. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, Wylie K. British Society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med 2008, 5:1841-65.
8. Brien JC, Trussell JC. Erectile dysfunction for primary care providers. Can J Urol 2008, 15(1):63-70. suppl
9. Teixeira CE, Lorenzetti R, Okuyama CE, Baracat JS, Donato JL, Antunes E, De Nucci G. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008, 591:189-95.
10. MDS Pharma Services Pharmacology Data Report on Compound CQ-2 for Cristalia Report # 1103605, April, 11 2008, data on file.
11. ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals CPMP/ICH/286/95. http://www.emea.europa.eu/pdfs/human/ich/028695en.pdf, Available at: (accessed October 4, 2009
12. Zincaglia LCM, De Angelis K, Taricano ID, Pagani E. Toxicidade oral aguda do carbonato de lodenafila em camundongos. Int Braz J Urol 2007, 33(2):PC0593. suppl
13. Taricano ID, Zincaglia LCM, Nicolau AA, Pagani E. Toxicidade oral aguda do carbonato de lodenafila em cães. Int Braz J Urol 2007, 33(2):PC0606. suppl
14. Zincaglia LCM, Taricano ID, De Angelis K, Bonamin LV, Pagani E. Toxicidade doses repetidas para carbonato de lodenafila em ratos. Int Braz J Urol 2007, 33(2):PC0575. suppl
15. De Nucci G. Estudo clínico fase I do carbonato de lodenafila em voluntarios sadios do sexo masculino. Int Braz J Urol 2007, 33(2):PC0627. suppl
16. Toffoletto O, Lucio LAG, Santos PF, Pagani E, Afiune J, Massud J, Silva AC, Tufik S. Estudo dos efeitos da alimentação e do álcool sobre a farmacocinética do carbonato de lodenafila, um novo inibidor da PDE5. 2008, http://sec.adtevento.com.br/fesbe/inscricao/mostra_resumo.asp?traId=1&insId=3241, Abstract 27-021 presented to FESBE, Available at: (accessed October 4, 2009
17. Silva AC, Tofolletto O, Lucio LAG, Santos PF, Afiune JB, Massud Filho J, Tufik S. Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. Arq Bras Cardiol 2009, 93.
18. Glina S, Toscano I, Gomatzky C, de Góes PM, Júnior AN, Claro JF, Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: A phase II clinical trial. J Sex Med 2009, 6:553-7.
19. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999, 54:346-51.
20. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997, 49:822-30.
21. Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): A state of the science review. Int J Impot Res 2002, 338:1397-404.
22. WHO-UMC Causality Assessment System [on line]. http://www.who-umc.org/graphics/4409.pdf, UPPSALA Monitoring Centre, Available at: (accessed August 4, 2008
23. Meyboom RHB, Royer RJ. Causality classification in pharmacovigilance centers in the European community. Pharmacoepidemiol Drug Saf 1992, 1:87-97.
24. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: A randomized, double-blind, pooled crossover study. J Sex Med 2006, 3:1037-49. Vardenafil-Sildenafil Comparator Study Group
25. Demir E, Balal M, Paydas S, Sertdemir Y, Erken U. Efficacy and safety of vardenafil in renal transplant recipients with erectile dysfunction. Transplant Proc 2006, 38:1379-81.
26. Hatzichristou D, Cuzin B, Martin-Morales A, Buvat J, Porst H, Laferriere N, Bandel TJ, Montorsi F. Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med 2005, 2:109-16. Vardenafil Study Group
27. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998, 338:1397-404.
28. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001, 13:2-9.
29. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001, 13:192-9.
30. Glina S, Bertero E, Claro J, Damião R, Faria G, Fregonesi A, Jaspersen J, Mendoza A, Mattos D, Rocha LC, Sotomayor M, Telõken C, Ureta S, Zonana E, Ugarte F. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in Latin America. Braz J Urol 2001, 27:148-54.
31. Rubio-Aurioles E, Casabé A, Torres LO, Quinzaños L, Glina S, Filimon I, Kopernicky V, Leñero E. Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: Results of integrated analyses. J Sex Med 2008, 5:1965-76.
32. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006, 60:967-75.
33. Carson CC. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005, 96:37M-41M.
34. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004, 110:3149-55.
35. Lorsheyd A, de Lange DW, Hijmering ML, Cramer MJ, van de Wiel A. PR and OTc interval prolongation on the electrocardiogram after binge drinking in healthy individuals. Neth J Med 2005, 63:59-63.
36. Leslie SJ, Atkins G, Oliver JJ, Webb DJ. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 2004, 76:265-70.
37. Wensing G, Bauer R, Unger S, Rohde G, Heinig R. Simultaneous administration of vardenafil and alcohol does not result in a pharmacodynamic or pharmacokinetic interaction in health male subjects. Int J Clin Pharmacol Ther 2006, 44:216-24.